Atlas
Back to RCM
Legal / Service Provider·RCM

Geoffrey C. Cockrell

Partner, healthcare private equity and M&A (immediate past chair of the firm's private equity group) at McGuireWoods LLP

Chicago, Illinois

GC
Why they matter

Runs the deal bench for healthcare provider-services roll-ups: he papers the PPM, DSO and billing-compliance structures that decide whether an RCM-dependent platform survives diligence.

Background

Geoff Cockrell is a partner at McGuireWoods in Chicago and the immediate past chair of the firm's private equity group, which he led for over a decade; he also formerly served on the firm's Board of Partners. His M&A and financing practice represents private equity sponsors, strategic buyers and sellers, with a primary focus on healthcare provider services transactions across ophthalmology, dental, dermatology, physical therapy, behavioral health and fertility. He holds a JD from Notre Dame Law School (magna cum laude, 1997) and a BA in business/economics from Wheaton College (1993), and is a Chambers USA-ranked leading lawyer for Private Equity Buyouts in Illinois.

Notable deals

  • 2020
    Represented MoonSail Capital and Plenary Partners in their strategic partnership with Arbor Centers for EyeCare and Chicago Eye Institute to form Ocular Partners, a physician-led eye care platform for greater Chicago.
  • 2019
    Represented BelHealth Investment Partners and its dermatology platform NavaDerm in the add-on acquisition of Laser & Skin Surgery Center of New York, a leading cosmetic and Mohs dermatology practice.
  • 2022
    Named to Crain's Chicago Business' Notable Gen X Leaders in Accounting, Consulting & Law, cited as leader of McGuireWoods' private equity practice and a member of its board of partners.
  • 2026
    Led the banker-focused panel at McGuireWoods' Healthcare Private Equity and Finance Conference in Chicago (April 29-30), one of the largest healthcare PE gatherings in the US, which he co-hosts annually.

Call-prep brief

Background

  • Chicago-based McGuireWoods partner; immediate past chair of the firm's private equity group (led it for over a decade) and a former member of the Board of Partners.
  • JD, Notre Dame Law School (magna cum laude, 1997); BA, Wheaton College (1993).
  • Repeat counsel to lower-middle-market healthcare sponsors: Sheridan Capital, Shore Capital, Ridgemont, Linden, LLR, Audax, Silver Oak, BelHealth, Chicago Pacific Founders.

Current focus

  • Physician practice management and DSO consolidation: ophthalmology (Ocular Partners, Long Island Vision), dental (Chicagoland Smile Group, Smile Doctors), dermatology (NavaDerm), physical therapy, behavioral health and fertility.
  • Platform formation and add-on sequencing, secondary sponsor-to-sponsor sales, and independent-sponsor structures.

What they care about

  • Whether a roll-up is genuinely physician-led, and whether the back office (billing, coding, collections) survives payor and regulatory scrutiny. His July 2026 podcast with Wiks Moffat framed compliance as a deal asset rather than a cost center — surfacing missed revenue post-close.
  • Buyer quality and what defines an "A-caliber" asset in a thawing provider-services market.

Recent moves

  • Hosts *The Corner Series* and writes The Healthcare Investor; co-hosts the annual McGuireWoods Healthcare PE and Finance Conference (led the banker panel, April 2026).

Potential sensitivities

  • He is outside counsel, not a principal: he will not name live mandates, unannounced deals, or client economics, and a conflicts check may precede substantive discussion. Avoid asking him to rank sponsors he serves.

Questions to ask

  1. In provider-services diligence, what RCM red flags kill a deal versus get priced into the QoE?
  2. Where are payor mix and coding-integrity issues showing up in secondary sales of PPM platforms?
  3. Which structures are holding up under corporate-practice-of-medicine scrutiny in your active states?

Outreach draft

Subject
Provider-services RCM diligence: 20 minutes?
Geoff — I lead diligence on healthcare provider-services platforms, and revenue cycle is where our theses keep breaking. Your Corner Series episode on compliance as a deal asset framed something we argue about internally: whether billing and coding cleanup is a genuine value-creation lever post-close or only downside protection. We're mapping the RCM layer underneath PPM and DSO roll-ups and would value 20 minutes on what you're seeing in structures and buyer appetite this cycle — no live mandate, just calibration before we commit capital. Happy to work around your conference schedule. Would a call in the next two weeks work? Best, [Your Name]

Linked companies

Sources